2. Johnson & Johnson
J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field. Maybe it's still reeling from its lost bid for Pharmacyclics. Those feelings of disappointment should wane as J&J cashes in on its half of blood-cancer drug Imbruvica's winnings. While annual earnings dipped last year, mainly due to a strong dollar and stifling competition for its hep.-C drug Olysio, J&J has a combo approach up its HCV sleeve that could give Gilead's Sovaldi and Harvoni a run for its money. RA treatment Remicade remains vulnerable to biosimilars, including Pfizer/Celltrion's Remsima. SGLT2 inhibitor Invokana for type 2 diabetes and Janssen Biotech/Genmab's Darzalex, approved in 2015 for multiple myeloma, should fill some of the gaps.